Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? (Q37054153)

17 August 2017

1 reference

title

Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? (English)

1 reference

17 August 2017

1 reference

1 reference

Celestia S Higano

1

1 reference

PubMed ID

18185511

17 August 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

17 August 2017

Nature Reviews Urology

1 reference

17 August 2017

5

1 reference

17 August 2017

1

1 reference

17 August 2017

24-34

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpuro0995

17 August 2017

0 references

cites work

Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Insulin sensitivity during combined androgen blockade for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Androgen deprivation therapy: monitoring and managing the complications

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Sex steroids and the construction and conservation of the adult skeleton

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Risk of fracture after androgen deprivation for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

The Influence of Osteoporotic Fractures on Health-Related Quality of Life in Community-Dwelling Men and Women across Canada

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Background for studies on the treatment of male osteoporosis: state of the art.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Aromatase inhibitors and bone health in women with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Applications of bone densitometry for osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Low bone mineral density in hormone-naïve men with prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

The relationship between daily calcium intake and bone mineral density in men with prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Bone matters: are density increases necessary to reduce fracture risk?

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Do men and women fracture bones at similar bone densities?

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Undertreatment of osteoporosis in men with hip fracture

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Transmission of human herpesvirus 8 by blood transfusion

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Cancer-treatment-induced bone loss, part 2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Therapy Insight: osteoporosis during hormone therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0995

7 January 2021

Identifiers

DOI

10.1038/NCPURO0995

1 reference

17 August 2017

1 reference

PubMed ID

18185511